期刊文献+

卡维地洛治疗慢性心力衰竭并心律失常60例疗效分析 被引量:11

The efficacy evaluation of carvedilol in the treatment of 60 chronic heart failure patients with arrhythmias
原文传递
导出
摘要 目的探讨卡维地洛治疗慢性心力衰竭并心律失常的疗效。方法120例慢性心力衰竭并心律失常患者随机分为治疗组和对照组各60例,对照组给予常规治疗,包括贝那普利、地高辛、呋塞米或氢氯噻嗪、螺内酯等治疗,治疗组在对照组治疗的基础上加用卡维地洛,随访12周,比较两组治疗前后血压、左室射血分数、心律失常缓解情况及疗效。结果治疗组在降低心率、纠正室上性期前收缩、室性期前收缩、室性心动过速及射血分数等明显优于对照组(t=6.018、5.319、7.623、6.194、7.562,P〈0.01);治疗组显效43例、有效15例、无效1例、死亡1例、总有效率96.7%,对照组分别为24例、14例、17例、5例、63.3%,两组总有效率差异有统计学意义(x2=34.301,P〈0.05)。结论卡维地洛在改善心功能、减少心律失常、降低病死率等方面,疗效肯定。 Objective To investigate the clinical effect of carvedilol in the treatment of chronic heart failure patients with arrhythmia. Methods 120 cases of hospitalized cases of cardiology were randomly divided into treatment and control groups by checking the random number table. The control group was given benazepril hydrochloride combined digoxin cardiac medicine and furosemide or hydrochlorothiazide, spironolactone and other diuretics in the treatment. The treatment group was given carvedilol based on the treatment of the control group. Followed up for 12 weeks, the clinical manifestations, blood pressure and heart rate, left ventricular ejection fraction(EF) and arrhythmias before and after treatment were obsered, and to determine the efficacy. Results The treatment group decreased heart rate, corrected ventricular premature contraction, ventricular contraction and ventricular tachycardia in comparison with the control group with significant differences ( t = 6.018,5.319,7. 623,6.194,7. 562, all P 〈 0. 001 ), and there was a significantly statistical significance( P 〈0. 01 ) that the treatment group can increase the ejection fraction compared with the control group. The markedly and total efficiency was more effective in the treatment group than the control group,which was statistically significant( x2 = 34. 301 ,P 〈0. 05 ). Conclusion There was a positive effect of carvedilol in improving heart function, reduceing arrhythmias and mortality, and reducing hospitalization rate and other aspects.
作者 陈伟宁
出处 《中国基层医药》 CAS 2012年第6期839-841,共3页 Chinese Journal of Primary Medicine and Pharmacy
关键词 心力衰竭 充血性 心律失常 卡维地洛 Heart failure, congestive Arrhythmia Carvedilol
  • 相关文献

参考文献11

  • 1ACC/AHA. Tast Force on Practice Guielines Committee to revise the 1995 guideline for the evaluation and management of heart failure. J Am Coil Cardiol,2001,108(38) :2101-2112.
  • 2Christian TP, Marco M, Andrew C, et al. Effects of metoprolol and carvedilol on preexisting and new onset diabetes in patients with chronic heart failure : data from the Carvedilol Or Metoprolol European Trial(COMET). Heart,2005,149 ( 2 ) :968-973.
  • 3Robert E, Shaddy, MD, Mark M, et al. Carvedilol for Children and Adolescents With Heart Failure A Randomized Controlled TriM. JAMA,2007,298 ( 10 ) : 1171-1179.
  • 4Friedrich M,Astrid FP,Rudolf B,et al. Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. Eur Heart J,2007,28(13) :1592-1597.
  • 5Raffael F, Fabio GF, Fabiana R, et al. Exercise training reduces sympathetic nerve activity in heart failure patients treated with carvedilol. Eur J Heart Fail, 2007,9 ( 6 -7 ) : 630-636.
  • 6Dirk JV, Kenneth D, Alain CS, et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemi. Eur Heart J,2007,28(18) :2208-2216.
  • 7Marco M, Loredana C, Natalia P, et al. Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-block-ade with carvedilol in patients with chronic heart failure. Cardiovascular Drugs and Therapy,2010,24( 1 ) :49-60.
  • 8Cecilia L, William T, Michael R, et al. Randomized Trial of Cardiac Rcsynchronization in Mildly Symptomatic Heart Failure Patients and in Asymptomatic Patients With Left Ventricular Dysfunction and Previous Heart Failure Symptoms. J Am Coll Cardiol,2008,52 (23) : 1834-1843.
  • 9Gregg CF, William TA, Nancy MA, et al. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA,2007,297 (1) :61-70.
  • 10Laurent F, Bertrand P, Axelde L, et al. Comparison of the beneficial effect of beta-blockers on mortality in patients with ischaemic or non-ischaemic systolic heart failure : a meta-analysis of randomised controlled trials. Eur J Heart Fail ,2007,9 ( 11 ) : 1136-1139.

同被引文献84

  • 1刘龙粉,朱庆勇,陶长生.P波离散度与房性心律失常的相关性分析[J].实用心电学杂志,2010,19(5):337-338. 被引量:4
  • 2叶义红,刘岚,陈卫城.多巴胺、地高辛、ACEI、呋塞米联合用治疗难治性心衰21例疗效观察[J].临床军医杂志,2005,33(6):732-733. 被引量:4
  • 3吴少琴,卢益中.P波离散度与阵发性心房颤动关系分析[J].心电学杂志,2006,25(2):92-92. 被引量:11
  • 4黄从新,马长生,杨延宗,黄德嘉,张澍,江洪,杨新春,吴书林,马坚,刘少稳,李莉,曹克将,王方正,陈新.心房颤动:目前的认识和治疗建议(二)[J].中华心律失常学杂志,2006,10(3):167-197. 被引量:269
  • 5张抒扬 戴玉华.全国高血压左室肥厚临床及基础研讨会纪要[J].中华内科杂志,1994,33(2):139-140.
  • 6刘力生,龚兰生.中国高血压防治指南[M].北京:中华人民共和国卫生部,2005:9-11.
  • 7Kamkin A, Kiseleva I, Wagner KD, et al. MechanicaUy induced potentials in atrial fibroblasts from rat hearts are sensitive to hypoxi- a/reoxy-genation. Ptlugers Arch,2008,446(2) :169-174.
  • 8Sata N, Hamada N, Horinouchi T, et al. C-reactive protein and at- rial fibrillation." Is inflammation a consequence or a cause of atrial fibrillation? Jpn Heart 2010,45 (3) :441-445.
  • 9Carom AJ, Kirehhof P, Lip GY, et al. Guidelines for the manage- ment of atrial fibrillation ..k the Task Force for the Management of At- rial Fibrillation of the European Society of Cardiology fESC ). Eur Heart J,2010,31 ( 3 ) :2369-429.
  • 10Asselbergs FW, van den Berg MP, Bakker S J, et al. N-terminal proB-type natriuretie pitide levelsPredict newly detected atrial fibril- lation in population-based cohort. NethHeart J,2008,16 (2) :73-78.

引证文献11

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部